Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib 1.5% Cream for Non-Sclerotic Chronic Cutaneous GVHD
NCT03954236Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2019
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib cream in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Body Surface Area at 28 days. Started May 2019; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03954236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954236.